Stock exchanges & markets

Overview Watchlists

DKSH Korea says MOHW expands Romiplate reimbursement for first-line severe aplastic anemia treatment

14. Aug 2026

(AWP Alliance News) - DKSH's Korea unit flagged an expansion in South Korea reimbursement for Romiplate as a first-line treatment for severe aplastic anemia, effective Aug. 1, 2026. The change covers use of romiplostim alongside standard immunosuppressive therapy in treatment-naïve patients, broadening access beyond prior second-line reimbursement limits. DKSH Korea cited a pivotal study showing a 76.5% overall response rate for the combination regimen versus about 50% at six months for historical immunosuppressive therapy alone.

https://www.publicnow.com/view/ECE85803A4B792F29FDD43F60D0EB37400F25554…

Disclaimer: This news brief was created using generative artificial intelligence. DKSH Holding AG published the original content used to generate this news brief on August 14, 2026, and is solely responsible for the information contained therein.

Learn more about our offers

  • Keep a close eye on your favourite shares

    Watchlist

    Don’t miss out on share price trends. Track your favourite shares (CH, EU & US) in real time with customised watchlists.

    Sign up now

  • ETF Compass

    Stock exchanges & markets

    ETFs are becoming increasingly popular. Our ETF Compass helps you maintain an overview. Filter by criteria such as asset class, region, rating, return or costs. 

    Try the ETF Compass now

  • How to find the best shares

    theScreener

    Search through around 6,500 securities using criteria such as opportunities and risks or expected dividend yield.

    Test now